Relationship between inflammatory markers, metabolic and anthropometric variables in the Caribbean type 2 diabetic patients with and without microvascular complications

Journal of Inflammation

Volumn 3, Issue , 2006, Pages

  Nayak, B Shivananda ^a   Roberts, Lesley ^b  

^a UNIVERSITY OF THE WEST INDIES   (Trinidad and Tobago)

^b EWMSC   (Trinidad and Tobago)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; SIALIC ACID;

ADOLESCENT; ADULT; ANTHROPOMETRY; ARTICLE; BLOOD PRESSURE MONITORING; CARDIOVASCULAR MALFORMATION; CENTRAL AMERICA; CONTROLLED STUDY; DIABETIC RETINOPATHY; DISEASE ASSOCIATION; ETHNICITY; HUMAN; HYPERTENSION; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MICROALBUMINURIA; MICROANGIOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; QUALITY OF LIFE; RISK ASSESSMENT; WAIST HIP RATIO;

EID: 33846626853     PISSN: None     EISSN: 14769255     Source Type: Journal    
DOI: 10.1186/1476-9255-3-17     Document Type: Article

References (32)

1. Five leading causes of death - 1999. Port of Spain: Central Statistical Office of Trinidad and Tobago; 2000.
2. Barcelo A, Aedo C, Rajpathak S, Robles S: The cost of diabetes in Latin America and the Caribbean. Geneva: World Health Organization; 2003.
3. Haffner S, Greenberg A, Weston W, Chen H, Williams K, Freed M: Effect of Rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes. American Heart Association 2002, 106: 679-684.
4. Duncan BB, Schmidt M, James S, Pankow J, Ballantyne C, Couper D, Vigo A, Hoogeveen R, Folsom A, Heiss G: Low grade systemic inflammation and the development of type 2 diabetes: the atherosclerosis risk in communities study. American Diabetes Association 2003, 52: 1799-1805.
5. Nayak S, Bhaktha G: Relationship between sialic acid and metabolic variables in Indian type 2 diabetic patients. Lipids in health and disease 2005, 4: 15-19.
6. Yarema K: The sialic acid pathway in human cells. Baltimore: John Hopkins University; 2006.
7. Pickup JC: Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care 2004, 27: 813-823.
8. Hulley S, Cummings S, Browner W, Grady D, Hearst N, Newman T: Designing clinical research. 2nd edition. Philadelphia: Lippincott, Williams and Wilkins; 2001.
9. Waist to hip ratio calculator. Baltimore: University of Maryland Medicine.
10. Winzler Rt: Determination of serum glycoproteins. In Methods of Biochemical analysis Volume II. Edited by: Glick DT. Interscience publishers, Inc, New York; 1955: 298.
11. Crook MA, Pickup JC, Lumb PJ, Georgino T, Webb DJ, Fuller JH: Diabetes care 2001, 24: 316-322.
12. Lindberg G, Eklund GA, Gullberg B, Rastam L: Serum sialic acid concentration and cardiovascular mortality. Br Med J 1991, 302: 143-146.
13. Abdella N, Akanji A, Mojiminiyi O, Assoussi A, Moussa M: Relationship of serum total sialic acid concentrations with diabetic complications and cardiovascular risk factors in Kuwaiti Type 2 diabetics. Diabetes Research and Clinical Practice 2000, 50: 65-72.
14. Crook MA, Goldsmith L, Ameerally P, Lumb P, Singh N, Miell J, Russell-Jones D: Serum sialic acid, a possible cardiovascular risk factor is not increased in Fijian Melanesians with impaired glucose tolerance or impaired fasting glucose. Ann Clin Biochem 2002, 39: 606-608.
15. Lindberg G, Iso H, Rastum L, Lundblad A, Folsom AR: Serum sialic acid and its correlate in community samples from Akita, Japan and Minneapolis. USA International journal of epidemiology 1997, 26: 58-63.
16. Hangloo B, Kaul I, Zargar H: Serum sialic acid levels in healthy indiviuals. Journal of Postgraduate Medicine 1990, 36: 140-142.
17. Melajarvi N, Gylling H, Miettinen T: Sialic acids and the metabolism of low density lipoprotein. Journal of Lipid Research 1996, 37: 1625-1631.
18. Traving C, Schaver R: Structure and function and metabolism of diabetic control and complications. Cell Mol Life Sci 1998, 54: 1330-1349.
19. Phillip MH: Prevention of progression in diabetic nephropathy. Diabetes spectrum 2006, 19: 18-24.
20. English P, Williams G: Type 2 diabetes. In Ann NY Acad Sci Volume 1067. London: Martin Dunitz Ltd; 2001: 448-453.
21. Chen J, Gall M, Yokoyama H, Jensen J, Deckert M, Parvaing H: Raised serum silaic acid in NIDDM patients with and without Diabetic Nephropathy. Diabetes care 1996, 19: 130-134.
22. Yokoyama H, Jensen J, Myrup B, Mathiesen E, Ronn B, Deckert T: Raised serum sialic acid concentration precedes onset of microalbuminuria in IDDM. Diabetes care 1996, 19: 435-440.
23. Cholestrol: What you need to know. National Institutes of Health 2005.
24. Cholesterol levels may be influenced by low carbohydrate diets. Medical News Today 2006.
25. Jonathan V, Robert E: Dyslipidemia in Type 2 Diabetes. Epidemiology and Biochemistry 2003.
26. Charles Vega: Chronuc kidney disease should prompt evaluation of cardiovascular risk factors. Medscape medical news 2006.
27. Mimran A, Ribstein J, Du-Cailar G: Microalbuminuria in essential hypertension. Curr Opin Nephrol Hypertens 1999, 8(3): 359-363.
28. Crook M, Earle K, Morocutti A, Yip J, Viberti GC, Pickup JC: Serum sialic acid a risk factor for cardiovascular disease is increased in IDDM patients with microalbuminuria and clinical proteinuria. Diabetes care 1994, 17: 305-310.
29. Crook M, Tutt P, Pickup JC: Elevated serum sialic acid concentrations in NIDDM and its relationship to blood pressure and retinopathy. Diabetes care 1993, 16: 57-60.
30. Favier F, Jaussent I, Moullec N, Debussche X, Boyer M, Schwager J, et al.: Prevalence of Type 2 diabetes and central adiposity in La Reunion Island. Diabetes-Metabolism research and reviews 2005, 22: 1-12.
31. Welborn TA, Dhaliwal SS, Bennett SA: Waist-hip ratio is the dominant risk factor predicting cardiovascular death in Australia. Medical Journal of Australia 2003, 179: 580-585.
32. Raz I, Skyler JS, Sharfrir ES: Diabetes: from research to diagnosis and treatment. Taylor & Francis group 2003, 24: 395-408.